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Protein interaction network of alternatively spliced
isoforms from brain links genetic risk factors
for autism
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Increased risk for autism spectrum disorders (ASD) is attributed to hundreds of genetic loci.
The convergence of ASD variants have been investigated using various approaches, including
protein interactions extracted from the published literature. However, these datasets are
frequently incomplete, carry biases and are limited to interactions of a single splicing isoform,
which may not be expressed in the disease-relevant tissue. Here we introduce a new
interactome mapping approach by experimentally identifying interactions between
brain-expressed alternatively spliced variants of ASD risk factors. The Autism Spliceform
Interaction Network reveals that almost half of the detected interactions and about 30% of
the newly identiﬁed interacting partners represent contribution from splicing variants,
emphasizing the importance of isoform networks. Isoform interactions greatly contribute to
establishing direct physical connections between proteins from the de novo autism CNVs.
Our ﬁndings demonstrate the critical role of spliceform networks for translating genetic
knowledge into a better understanding of human diseases.
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A
utism spectrum disorder (ASD) is a broad class of
neurodevelopmental disorders with a common set of core
features including social impairments, communication
difﬁculties and repetitive behaviours. The genetic aetiology of
ASDs is also highly heterogeneous and can be attributed to
hundreds of genes, of which only a small fraction have sufﬁcient
genetic evidence to be considered as causative. Some of the most
well-documented autism risk factors include genes associated
with rare syndromic forms of ASD (MECP2, FMR1, PTEN),
synaptic cell adhesion and scaffolding molecules (NLGN3,
NLGN4, NRXN1, CNTNAP2, SHANK3) and genes with de novo
mutations (CHD8, SCN2A, DYRK1A among others) recently
identiﬁed in exome-sequencing studies1–4. Copy number
variation (CNV)5–7 and genome-wide association studies8–10
have discovered rare and common variants, respectively, that
confer varying effects on ASD risk in the general population.
The heterogeneity of genes implicated in ASD stimulated
intensive testing of the pathway convergence hypotheses11. The
experimental and computational approaches including gene
coexpression12,13, functional annotations14,15, mouse model
phenotypes16 and protein–protein interactions (PPIs)3,17,18 were
used to search for molecular processes and pathways shared by
the ASD risk factors. With regard to convergence at the protein
interactions level, only one experimental PPI study of 35
syndromic ASD genes is currently available17; all other PPI
studies in ASD to date have been based on the interactions
extracted from the published literature. However, literature PPI
datasets are known to be incomplete and inherently biased19.
For example, the largest database of autism candidate genes,
‘Simons foundation autism research initiative (SFARI) gene’
(https://sfari.org/resources/sfari-gene), contains human binary
physical protein interaction annotations for only 24% (131/546,
June 2013 release) of its entries. The annotations of interactions
between ASD genes, which is even more important for
discovering the desired convergence, is scarcer still—only 9%
(50/546) of SFARI proteins are annotated as interacting with each
other. In addition, literature interactions carry a wide range of
other biases: highly studied proteins have a greater number of
interactions, computationally predicted, erroneously annotated
and non-binary interactions may be included in the analyses19,20.
Most importantly, the interactions of the alternative splice
forms of genes have not been systematically incorporated
into disease networks, even though most human genes are
alternatively spliced21,22. Historically, only a single so-called
‘reference’ isoform of each gene (or its fragments) has been used
in the disease PPI network studies17,23–25.
Here we apply a novel approach to mapping an ASD
interactome network by experimentally testing multiple naturally
occurring brain-expressed alternatively spliced isoforms of nearly
200 autism candidate genes for interactions. In addition, we also
test all cloned splicing isoforms of these genes for interactions
against themselves and identify important novel PPIs between
variants of the ASD risk factors. We demonstrate that the
resulting Autism Spliceform Interaction Network (ASIN) pro-
vides greater detail and depth around ASD proteins than the
conventional PPI networks. ASIN directly connects genes from a
large number of ASD-relevant CNVs into a single connected
component. We identify two proteins as important connectors
between CNV loci, and implicate new players in ASD. Overall,
our isoform-based autism interactome provides the detailed and
unprecedented look at the cellular network involving a large
number of ASD risk factors.
Results
Constructing autism brain-expressed isoform ORF library. To
obtain a network of physical interactions between proteins
implicated in autism, we performed global interactome mapping
for 191 autism candidate genes and their cloned brain-expressed
splice variants (Fig. 1a). The list of selected ASD risk factors
(Methods, Supplementary Data 1) consisted of genes associated
with syndromic forms of ASD (for example, TSC2 and FMR1; a
total of 24); genes affected by the de novo CNVs (for example,
ARID1B and A2BP1 also known as RBFOX1; a total of 65) or
recurrent CNVs (for example, PTCHD1 and CNTN4; a total of
27); genes carrying rare mutations in autism patients (for
example, SCN2A and GRIN2A; a total of 25), and genes with
suggestive evidence for association with autism (for example,
CDH9 and CDH10; a total of 50). Recently, a rapidly growing
number of genes have been implicated in ASD with varying
degrees of conﬁdence: from very strong for a handful of the
syndromic genes to suggestive for hundreds of genes from the
CNV and the genetic-association studies. As a result, an attempt
to prioritize ASD candidate genes is inevitably subjected to a
range of biases. Here, we decided to create a broad list of non-
syndromic ASD candidates by including all genes with suggestive
evidence that were available in the published literature at the time
when this study began (early 2010), in addition to the genes with
strong evidence from the syndromic ASD studies. Since our study
began before the publication of ASD exome sequencing studies1–
4, the new genes with de novomutations identiﬁed in these studies
were not included in our candidate gene list.
Using total RNA (Clontech, Stratagene) puriﬁed from the
pooled foetal and adult whole brain samples (Methods) and
applying a high-throughput isoform discovery pipeline and deep-
well next-generation sequencing26, we successfully cloned 373
brain-expressed splicing isoforms corresponding to 124 autism
candidate genes (Supplementary Fig. 1). To further increase the
coverage, the set of cloned isoforms was supplemented with
additional open reading frames (ORFs) from the human
ORFeome 5.1 (ref. 27) resulting in a library of 422 splicing
isoforms for 168 genes (ASD422, Fig. 1a, Supplementary Data 2).
While the isoform space coverage in our study is limited to an
average of B2.5 isoforms per gene, the advantage of our
approach lies in the creation of the physical collection of the
full-length splicing isoforms that is not available from the RNA-
seq studies.
By comparing the full-length sequences of the cloned isoforms
to the full-length sequences annotated in six public databases
(consensus coding sequence (CCDS), RefSeq, GenCode, UCSC,
MGS and ORFeome) we observed that over 60% of the cloned
isoforms are novel—that is, have not previously been reported in
any of these databases (Fig. 1b). The distribution of novel and
known cloned splicing variants among different subclasses of
genes selected for this study was fairly uniform, and only genes
with rare mutations had slightly decreased fraction of cloned
novel isoforms (Fig. 1b). Considering that the brain is among the
tissues with the highest frequency of alternative splicing events22,
the large number of novel isoforms that we cloned was not
unexpected. Furthermore, the high fraction of novel brain-
expressed isoforms is consistent with a previous study that also
identiﬁed the highest proportion of novel isoforms in the brain
while investigating ﬁve different tissue types26.
We examined the splicing patterns by which novel isoforms
were produced. We observed that according to previously
introduced classiﬁcation21, most novel isoforms were generated
using either ‘bounded’ exons (47%) that contain partial fragments
of known exons, or by reshufﬂing of known exons (32%)
(Fig. 1b). The remaining isoforms had at least one new exon (8%)
that did not overlap with any known exons, or had an ‘extended’
exon (13%) consisting of a known exon extended with the
adjacent novel exonic region. The cloned splicing variants of
three genes (NDE1, RIMS3 and RAPGEF4) demonstrate that
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isoforms may carry different types of exons or combinations of
exons (Fig. 1c).
Autism spliceform interaction network. To build an autism
spliceform interaction network (ASIN), the ASD422 isoform library
was tested in two independent high-throughput yeast-two-hybrid
(Y2H) screens (Fig. 1a). The ﬁrst screen tested 422 ORFs for
interactions against the human ORFeome 5.1 (ref. 27) comprising
B15,000 ORFs. The second screen tested interactions among the
ASD422 ORFs themselves. Isoform interactions identiﬁed in these
screens using next-generation sequencing were subsequently
conﬁrmed by Sanger sequencing (Supplementary Fig. 2, Methods).
To increase conﬁdence of detected isoform interactions and to
ensure that interaction changes are indeed owing to alternative
exon usage by the isoforms, all corresponding protein isoforms
for any given gene were Y2H-retested four times in a pair-wise
format against the full series of interactors of any protein isoform
of that gene found in the primary screens, thereby controlling for
potential biases owing to sampling sensitivity (that is, all isoforms
against all interaction partners of any isoform of that gene). Only
the interactions that scored positive at least three times in the
retests were retained, and only those isoforms with at least one
interacting partner were used for the subsequent analyses. Finally,
the isoforms without any interacting partners were eliminated
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Figure 1 | Splicing isoform cloning and construction of autism spliceform network. (a) The experimental pipeline used to construct ASIN.
High-throughput splice isoform discovery and cloning was performed for 191 ASD risk factors using total RNA puriﬁed from the pooled foetal
and adult whole brain samples. A total of 422 splicing isoforms of these genes were assayed by Y2H screens for interactions against 15,000 human
ORFs (ASD422 versus ORFeome) and against themselves (ASD422 versus ASD422) to construct the ASIN with 629 isoform-level PPIs. (b) Novelty
assessment of the discovered splice isoforms. Isoform novelty was evaluated based on the annotations from six public databases. The ratios of known
and novel cloned isoforms among different categories of ASD risk factors is uniform, with genes with rare mutations having slightly lower number of
cloned novel isoforms. Exons used to generate novel isoforms were assigned in the following order: ‘isolated’, ‘extended’, ‘bounded’ and ‘shufﬂed’.
The majority of novel isoforms were generated using ‘bounded’ exons. (c) The examples of cloned isoforms carrying four types of exons. An intronic
region of NDE1 is converted into a coding region (‘isolated’); the exon 2 of RIMS3 is extended with an intronic region (‘extended’); the partial deletion
of the ﬁrst two exons of RAPGEF4 (‘bounded’) and a novel exonic combinations in all three genes (‘shufﬂed’) are shown. The introns are not to scale.
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from the analyses and were not considered as having lost
interactions (that is, negatives).
We detected 506 positive physical binary PPIs (corresponding
to 629 isoform-level PPIs) between 71 baits (autism risk factors)
and 291 preys (genes from the human ORFeome collection or
from ASD422 isoform library; Supplementary Data 3–5). Most
(463/506 or 91.5%) of the detected PPIs were novel, based on a
comparison with a comprehensive literature-curated interaction
dataset (LCI) of over 35,000 high-conﬁdent physical binary
interactions assembled from seven public databases (MIPS,
BIND, DIP, MINT, IntAct, BioGRID and PDB) (Supplementary
Methods).
Validation of ASIN interactions by mammalian PPI trap assay.
To ensure that we have constructed a high-quality network, 312
interaction pairs corresponding to 62% of gene-level interactions
in ASIN were retested in an orthogonal assay, mammalian PPI
trap assay (MAPPIT)28, and then benchmarked against a positive
reference set (PRS) and a random reference set (RRS), consisting
of B500 and B700 protein pairs, respectively. The ASIN
validation set was assembled by following a two-tier procedure
(Methods) and consisted of the interacting protein pairs unique at
a gene-level but at the same time represented by a diverse set of
the isoforms. The validation rate of ASIN interactions was similar
to that of PRS (nASIN¼ 312 versus nPRS¼ 460, Wilcoxon
P¼ 0.85) and was signiﬁcantly higher than that of RRS
(nASIN¼ 312 versus nRRS¼ 698, Wilcoxon P¼ 1.78  10 11;
Fig. 2a). The precision of ASIN (89.2%) estimated at the RRS
recall rate of 0.01 was comparable to that of two other
interactome networks, human (79%)29 and Arabidopsis (80%)30.
To conﬁrm the biological relevance of the detected inter-
actions, we also examined coexpression, coregulation and
cofunctional annotation of all ASIN protein pairs using Gene
Ontology (GO) terms (Methods). Interacting protein pairs from
ASIN were signiﬁcantly enriched in the coexpressed pairs, in the
pairs that share transcription factor-binding sites and in the pairs
with shared GO terms when compared with random pairs of
proteins (Fig. 2b). Furthermore, the interacting protein pairs from
ASIN formed binary protein complexes with experimentally
solved or homology-modelled structures more frequently than
random pairs (Methods). High retest rate of ASIN interactions
in the mammalian system together with its enrichment in pairs
with shared functional annotations and structures suggest that
ASIN is a high-quality network of biologically-relevant interac-
tions. Most importantly, ASIN is the ﬁrst high-resolution disease
network built using multiple full-length splicing isoforms of
hundreds of genes, all derived from a disease-relevant brain
tissue.
Splicing isoform interactions expand ASIN. Typically, a PPI
screen will test only a single ‘reference’ isoform of each gene. We
investigated whether additional isoform interactions detected in
our study expand this ‘reference’ network and add new isoform-
speciﬁc PPIs. We constructed the ‘reference’ ASIN network by
including only interactions corresponding to a single, ‘reference’
isoform (typically CCDS ORF) of each ASIN gene (Fig. 3a). We
observed that this ‘reference’ network comprises approximately
half of all detected PPIs. The remaining 46% of the isoform-level
PPIs, corresponding to 33% of the gene-level PPIs, would not
have been identiﬁed if we only screened ‘reference’ isoform of
each gene for interactions (Fig. 3b). Notably, many PPIs that we
have identiﬁed were derived exclusively from the non-reference
isoforms, emphasizing the importance of isoform screening for
building more complete PPI networks.
In addition to expanding the ‘reference’ network, new ASIN
PPIs also expanded the LCI network of previously reported
high-quality binary physical interactions from the published
literature (Supplementary Methods). ASIN interactions increased
the public network of interactions by 51% by adding 463 novel
previously unreported physical associations (Fig. 3c). For some
important ASD risk factors, such as forkhead box protein P2
(FOXP2) and A2BP1, the ASIN doubled and tripled the number
of previously known interactions, respectively. In addition,
28% of the interactions we detected involve genes for which no
interactions have been reported in the public databases, for
example TBX6 and DGCR6 among the others.
The mechanism by which splicing could inﬂuence PPIs and
expand networks is directly related to the retention and loss of
speciﬁc exons. For example, the A2BP1 gene coding for the
ataxin-2 binding protein 1 has 16 coding exons, and at least ﬁve
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Figure 2 | Autism spliceform network quality assessment. (a) ASIN validation rate in the orthogonal mammalian system MAPPIT. Y-axis shows the
fraction of ASIN, positive reference protein pairs set (PRS) and random reference set (RRS) pairs recovered by MAPPITat increasing RRS recovery rates; 1%
RRS recovery rate is indicated by a vertical dotted line. The shading indicates standard error of the proportion. The validation success rate of ASIN is
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versus nRRS¼ 698 P¼8.1  10 12; two-sided Wilcoxon rank sum tests). (b) Interacting ASIN pairs are signiﬁcantly enriched in coexpressed, coregulated
and co-GO-annotated protein pairs, as well as in protein pairs forming binary complexes with experimentally solved or homology-modelled structures.
The comparison was performed against the background control dataset that consisted of B1.2 million non-redundant protein pairs generated by pairing
each ASIN protein with each protein from the human ORFeome 5.1. P-values were calculated using one-tailed Fisher’s exact test.
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of them could be alternatively spliced. We cloned two new
isoforms of A2BP1, A2BP1_A and A2BP1_B (Fig. 3d). When we
tested different isoforms of A2BP1 for interactions, we observed
signiﬁcant variability in their interaction partners: only three
interaction partners were shared among three isoforms, two
partners were shared among two isoforms, and four partners were
exclusively interacting with only one isoform (Fig. 3d). Further
analysis demonstrated that inclusion or exclusion of speciﬁc
exons is directly correlated with the observed PPI differences of
the isoforms: differential usage of exon 8 inﬂuences interaction
with CRX1; of exon 10a—with BHLHE40; of exon 10b—with four
unique partners. These results suggest that differential exon usage
by the splice variants could expand or even alter PPI networks,
which may have important consequences for cellular function
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and disease, as was previously demonstrated for two splicing
isoforms of the pyruvate kinase in cancer31.
ASIN preys are enriched in genes from rare de novo CNVs.
Approximately half of autism risk factors (that is, ASIN baits)
selected for this study are located within rare de novo or recurrent
CNVs that have been identiﬁed in the patients, with many of
them conferring high risk for ASD (Supplementary Data 1). Thus,
the ASIN network contains information on protein interactions
of genes from different CNV loci. We investigated whether there
was evidence of genetic association with ASD among the ‘prey’
proteins, that is, the interacting partners of the ASD candidate
genes that were identiﬁed by an unbiased screen against human
ORFeome (B15,000 ORFs).
We assembled a dataset of 198 de novo validated autism CNVs
containing 2,267 genes by combining CNV discovery results from
ﬁve studies5–7,14,32. Two larger networks, Human Interactome
space II 2011 (HI-II-11) and literature LCI were used as controls
for this analysis (Methods). We then mapped the genes from de
novo CNVs to the ASIN and HI-II-11 prey space (all ASIN baits
were excluded from this analysis to eliminate the apparent CNV
bias of the ASD422 list). We observed a 1.5-fold enrichment of
ASIN preys in genes from de novo autism CNVs compared with
the HI-II-11 preys (15.5 versus 10.6%, Fisher’s exact P¼ 0.013;
Supplementary Fig. 3a, Supplementary Table 1). Similar
signiﬁcant enrichments were observed when ASIN was
compared with the LCI dataset (15.5 versus 10.1%, Fisher’s
exact P¼ 0.0047), and when only brain-expressed genes from
all these datasets were analysed (Supplementary Fig. 3b,
Supplementary Table 1). These results suggest that proteins
encoded by pathogenic autism CNVs tend to physically interact
with the partners from other ASD CNVs, highlighting functional
connectivity between CNV risk loci in ASD.
Isoform interactions contribute to de novo CNV–prey
connectivity. To more deeply investigate the role of preys, we
prioritized them based on the number of the CNV nodes that
they connect in ASIN. Our underlying hypothesis is that network
prey proteins connecting greater number of genes from the
pathogenic CNVs may represent more interesting targets for
future studies. Thus, we performed a subsequent analysis by
merging ASIN baits from the same CNVs into the CNV nodes
(Fig. 4a). This procedure transformed ASIN into a CNV–prey
network, where ASIN risk factors (baits) are replaced with 17
CNV nodes that are connected through ASIN prey partners by
the isoform interactions. We also constructed 10,000 control
networks with the same characteristics as ASIN but using either
HI-II-11 or LCI interactions (Supplementary Fig. 4a).
We then focused our analysis on preys that link two or more
CNV nodes. We observed that 26 ASIN preys interact with a
signiﬁcantly larger than expected number of CNV nodes and
15/26 (58%) of these preys have at least one interaction supported
by a non-reference bait isoform (Fig. 4b, Methods). For example,
the majority (22/34 or 65%) of interactions that connect a high
risk ASD CNV 16p11.2 in the CNV–prey network are derived
exclusively from the non-reference isoforms. This suggests that
isoform interactions signiﬁcantly contribute to the increased
CNV connectivity observed in ASIN.
Two proteins, GOLGA2 and BZRAP1, linked as many as six
different CNV nodes in ASIN, which is a highly unlikely event to
occur by chance (empirical Po0.0001). In contrast, none of the
control networks contained preys that connected more than four
CNV nodes (Supplementary Table 2). Two out of six PPIs of
GOLGA2 and four out of six PPIs of BZRAP1 in the CNV–prey
network are supported exclusively by the non-reference isoform
interactions and would likely not have been detected by screening
only the reference isoforms of these genes. Both genes are
expressed in brain, and two recent studies have reported a
de novo CNV overlapping with GOLGA2 (refs 6,7). GOLGA2 is a
component of the Golgi involved in the transport of proteins and
lipids, a function that is consistent with its high connectivity.
BZRAP1 is a Rab3-interacting molecules (RIM)-binding protein
that also binds to voltage-gated calcium channels, constituting an
alternative link between RIM and calcium channels33. It was
previously suggested as ASD risk factor in a CNV study34. In
summary, the isoform-level PPIs support GOLGA2 and BZRAP1
as important connectors between multiple CNVs in ASIN.
An isoform-resolved network directly links de novo autism
CNVs. We demonstrated that genes from de novo autism CNVs
are connected in ASIN via prey partners. To explore whether
genes from different de novo CNVs directly interact with each
other at the protein level, we extended our analysis by merging
both ASIN baits and preys into the CNV nodes and constructing
a CNV–CNV network (Fig. 4a). The resulting network directly
linked all 27 autism CNVs mapped to ASIN into one connected
component (Fig. 4c). In contrast, the largest connected compo-
nent of 10,000 control networks generated by permuting the
locations of CNVs in the genome ranged from 1 to 12, which is
signiﬁcantly smaller than 27 for ASIN (empirical Po0.0001,
Methods, Supplementary Fig. 4b, Supplementary Table 2).
The CNV–CNV network directly connects proteins from
several recurrent de novo CNVs (16p11.2 and 22q11.21-22;
16p11.2 and 7q31.1-q32.1; 7q31.1-q32.1 and 15q11.1-q13.3). The
analysis of a more informative isoform-resolved CNV–CNV
network indicates that about one third (16/47 or 34%) of the PPIs
in this network are supported by the non-reference isoforms of
the genes that have two or more isoforms cloned in this study
(Supplementary Fig. 5). More importantly, the direct CNV
connections are mostly supported by novel interactions from
ASIN. For example, connection between the 16p11.2 and
22q11.21-22 CNVs is supported by a novel direct interaction of
Major vault protein (MVP) with RIMS-binding protein 3A
(RIMBP3). Likewise, the connection between the 16p11.2 and
7q31.1-q32.1 CNVs is supported by a novel direct interaction of
mitogen-activated protein kinase 3 (MAPK3) with FOXP2. A
major contributor to the high connectivity of 22q11.21-q11.22
CNV, which directly links 15 other CNVs, is the DiGeorge
syndrome critical region 6 protein DGCR6, for which no
experimentally detected interactions have been reported before
this study.
ASIN provides strong support for important functional
protein-level relationships between a large number of autism
CNVs. The observed direct physical associations between
proteins encoded by individually rare de novo CNVs points
towards common molecular networks shared among different
ASD patients.
ASIN preys as new protein players in autism. Despite a large
number of preys that we have identiﬁed in ASIN (a total of 291),
various types of subsequent analyses consistently highlighted a
small subset of preys as being more relevant to ASD (Methods).
To prioritize ASIN preys, we ranked them according to ten
independent (median Pearson’s correlation coefﬁcient (PCC)¼
 0.11) sources of evidence for implicating these preys in ASD
(Supplementary Fig. 6).
A total of 31 out of 291 ASIN preys, all notably being expressed
in brain, accumulated three or more sources of evidence (Fig. 5a,
Supplementary Data 6). Whereas 11/31 preys were previously
implicated in autism, the remaining 20 are proteins that had not
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Figure 4 | Spliceform interactions connect genes from autism CNVs. (a) Schematic representation of the CNV–prey and CNV–CNV networks
construction. The coloured horizontal bars spanning a chromosomal region represent different de novo CNVs identiﬁed in ASD patients. Genes from the
same CNVs projected (dashed coloured lines) to the ASIN network are outlined by coloured ellipses. To create a CNV–prey network, baits from the same
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CNV–CNV network, preys were also grouped into the CNV nodes connected by the ASIN PPIs. (b) The CNV–prey network (left) identiﬁes 26 preys (larger
and darker grey triangles/squares) that bind to signiﬁcantly greater number of CNV nodes than expected by chance. To identify such preys, the empirical
P-value for each prey was estimated using 10,000 degree-preserving rewired networks with exactly the same properties as ASIN. Only preys binding to
Z2 CNVs are shown. Dark blue edges are PPIs supported exclusively by the non-reference isoforms, tan edges—by the reference isoforms, light blue
edges—by both isoform types. The control network (right) was selected from 10,000 control networks constructed from the randomly selected genomic
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as in ASIN, connected by HI-II-11 PPIs. All networks were visualized using Cytoscape.
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yet been explicitly associated with ASD at the time when this
study began. Further investigation of the physical associations
between highly ranked preys demonstrated that the majority of
them (25/31 or 81%) interact with each other through the bait
nodes that were also captured in the prey conﬁguration in our
Y2H screens (Fig. 5b). More importantly, 82% of the PPIs
between highly ranked preys are supported exclusively by the
non-reference isoforms, 12% by both, reference and non-
reference isoforms and only 6% by exclusively reference isoforms.
Furthermore, 58% of the PPIs are supported by the novel
isoforms cloned in this study. This suggests that the majority of
the interactions in this prey network would have escaped
detection in the traditional reference-based PPI screens.
While our study was in progress, some of the ASIN preys have
started accumulating genetic evidence for autism relevance. For
example, a highly ranked prey TCF4 was recently identiﬁed as a
strong autism candidate in the whole genome sequencing of
monozygotic twins35; ﬁve preys (RIMBP3, GOLGA2, MKRN3,
C16orf45 and MAGED1) were found within newly reported de
novo CNVs6,7,14; and two other preys (CASK and DISC1) were
implicated in ASD based on a recent exome sequencing study4.
Accumulating evidence suggests that many genetic risk factors
are shared between different neurodevelopmental disorders36–39.
We examined whether newly identiﬁed ASIN preys are involved
in other neurodevelopmental syndromes characterized by
psychiatric phenotypes, such as intellectual disability, mental
retardation and developmental delay. We observed that ASIN is
signiﬁcantly enriched in preys involved in these disorders
compared with HI-II-11 (5.2% versus 2.6%, Fisher’s exact
P¼ 0.02, Supplementary Table 1, Supplementary Data 7), and
the enrichment is maintained when analysis is restricted to only
brain-expressed genes (6.1% versus 2.9%, Fisher’s exact P¼ 0.012,
Supplementary Table 1, Supplementary Methods).
Among 31 highly ranked ASIN preys, nine are relevant to other
psychiatric abnormalities (annotated as ‘psychiatric phenotype’
in Online Mendelian Inheritance in Man in Fig. 5a). The
transcription factor TCF4 is involved in Pitt-Hopkins syndrome,
which is characterized by mental retardation and distinctive
facial features40. Recently, de novo point mutations of TCF4 have
been implicated in developmental delay41–43 and autism35, and
common variants of TCF4 were recurrently implicated in
schizophrenia44,45. Similarly, mutations in the transcriptional
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inhibitor ZEB2 are the cause of Mowat–Wilson syndrome,
a complex developmental disorder characterized by mental
retardation, delayed motor development, epilepsy, microcephaly
and a wide spectrum of clinically heterogeneous features46. Other
psychiatric abnormalities with mutations in ASIN preys include
Prader–Willi (the 15q11.2 region, which includes MKRN3),
speech-language disorder (FOXP2), and lissencephaly (NDE1).
In addition, some CNV regions harbouring highly ranked preys
are associated with multiple phenotypes. For example, NDE1
is located in 16p13.11, a genomic region that is impacted by
CNVs in autism7,14, schizophrenia47, mental retardation48,49,
attention-deﬁcit hyperactivity disorder50 and epilepsy51.
Considering the above observations it is tempting to speculate
that the convergence of the risk factors for genetically- and
phenotypically-heterogeneous neurodevelopmental disorders
may occur at the level of protein interaction networks. In
summary, our study emphasizes the importance of isoform-
resolved PPI networks for improving understanding of autism
along with other neuropsychiatric diseases.
Discussion
Functional relationships between genes are difﬁcult to infer
through genetic approaches alone. Our study illustrates the power
of integrating genetic data with detailed isoform-resolved protein
interaction network to gain better knowledge about ASD. The
autism spliceform network constructed using brain-expressed
gene variants is more relevant to ASD than literature-based PPI
networks. ASIN has uncovered new direct physical associations
between genes from pathogenic autism CNVs. It also identiﬁed
new interacting partners of ASD risk factors through a large
unbiased screen against thousands of other human genes. Many
of the new interacting partners that we have discovered are
involved in other neurodevelopmental disorders. Further func-
tional analysis of these genes could signiﬁcantly deepen our
insight into pathogenesis of ASD and related disorders.
ASIN is a resource with a considerable value for genetics,
neurobiology and drug development. The collection of 422 cloned
brain-expressed isoforms of ASD candidate genes, along with
the high-quality interactome consisting of 629 isoform-based
protein interactions, represents an unprecedented resource for
future studies of autism. A comparison of ASIN with another
recently published autism network focused on 35 syndromic
autism genes17 that does not consider interactions from the
splicing isoforms, shows that these two networks are highly
complementary (Supplementary Fig. 7). Our study further
highlights the need to include alternatively spliced isoforms of
genes in future PPI screens to construct more comprehensive
disease-speciﬁc and tissue-speciﬁc interactomes. It is essential to
focus the disease network studies on the PPIs relevant to the
tissue and pathology. Given that autism is a developmental brain
disorder, the interactions identiﬁed from the brain-expressed
isoforms are more appropriate for the study of ASD than PPIs
from the public databases that may include interactions from the
variants that are not even expressed in the human brain.
Additionally, the changes in interactions of different splicing
isoforms should be taken into consideration when generating and
investigating disease-targeted networks.
The biological relevance of a disease network is of course
dependent on the disease relevance of the genes that were used to
construct it. Networks built based on the ﬁndings from the
genetic studies of complex diseases include a combination of true
disease-associated genes and other non-relevant genes, which are
expected to occur in the genetic data by chance. For example, in
recent exome sequencing studies of ASD, it is estimated that only
a fraction of the mutations detected in the patients (B10–20%)
inﬂuence disease risk1,4. Similarly, for CNVs (even ones that have
been deﬁnitively linked to ASD) only a subset of genes within the
genomic region may be relevant to autism. To achieve a balance
between the number of genes and the strength of evidence
supporting their involvement in ASD, we decided to focus our
network on the genetic variants that have strong effects, such as
de novo CNVs and those implicated in the syndromic forms of
ASD. In addition, we expanded the gene list with genes that have
suggestive evidence, including the results of genome-wide
association studies and functional studies of individual genes, to
encompass a broader spectrum of the disorder. We anticipate that
ASIN will be further reﬁned as knowledge of the underlying genes
contributing to ASD grows. So far, our study represents a
signiﬁcant step in this direction.
Disease-centered networks such as ASIN could serve as
valuable exploration tools for future studies. It is likely that some
mutations that are currently being identiﬁed in ASD patients
through exome- and whole-genome sequencing can impact or
even disrupt these networks. Continued progress in genetics will
rely heavily on parallel efforts to develop experimental and
computational methods to distinguish between deleterious and
neutral mutations. With the ASIN network constructed, we can
now begin to examine how disease mutations identiﬁed in the
patients impact this network, possibly through the interaction
perturbation mechanisms. Furthermore, our autism spliceform
network is an easily expandable resource that can keep pace with
rapid advances in genetics, incorporating new ﬁndings as they
emerge. Knowledge of interacting partners of ASD risk factors
has direct implications for the development of therapeutics.
A gene that has been ﬁrmly implicated in autism may not itself be
an ideal drug target; however, an exploration of its interacting
partners may identify more suitable drug targets.
Methods
Selection of the autism risk factors. Manually curated list of ASD risk factors
was compiled in the early 2010 (before the publication of three major de novo
CNV6,7,14 and exome sequencing1–4 studies) and consisted of 191 genes with
suggestive evidence for involvement in ASD from earlier literature (Supplementary
Data 1). In assembling this list we intentionally aimed at covering as broad variety
of the risk factors for non-syndromic ASD as possible, including those from
different types of CNVs, which lead to the list of genes with variable degree of
conﬁdence for ASD relevance. Besides syndromic ASD risk factors (B13% of the
dataset) and the genes from the de novo (B34%) and rare recurrent CNVs
(B14%), the remaining candidates included genes carrying rare high penetrant
mutations (B13%) and genes implicated in ASD based on other sources of
evidence such as animal models, alterations in expression in the postmortem brain
of ASD patients, genetic association studies and relevance to other psychiatric
disorders (B26%).
Brain-expressed isoform discovery pipeline. The high-throughput splice iso-
form discovery pipeline combines high-throughput cloning and next-generation
sequencing26. Brieﬂy, primers corresponding to the longest-annotated ORF of each
gene were designed (Supplementary Data 8) and the reverse transcription was
performed using the total RNA puriﬁed from the multiple pooled samples of the
adult and the foetal whole normal human brains (purchased from Clontech and
Stratagene). The adult brain sample contained puriﬁed whole brain RNA pooled
from two healthy donors, an 18 year old male (Clontech) and a 66 year old female
(Stratagene). The foetal sample contained puriﬁed whole brain RNA pooled at a
29.5:1 ratio from 59 spontaneously aborted male/female Caucasian foetuses, 20–33
w/o (Clontech), combined with two female foetuses 18 w/o (Stratagene). Reverse
transcripts of brain RNAs were used as templates for the PCR ampliﬁcation with
KOD HotStart Polymerase (Novagen) using designed primers. Reverse
transcription–PCR products were recombinationally cloned via a Gateway BP
reaction (Invitrogen) with the pDONR223 vector and resulting plasmids were
subsequently transformed into Escherichia coli DH5a-competent cells and grown
on LB-agar plates overnight at 37 C. A total of 32 single colonies were picked for
each gene and the ORF inserts were ampliﬁed by PCR using pDONR223 universal
primers (M13G forward and reverse). A total of 32 pools of PCR products were
created by distributing one colony from each gene per pool and DNA products
were puriﬁed using MinElute PCR Puriﬁcation Kit (Qiagen). Roche 454 GS FLX
sequencing was performed according to the manufacturer’s instructions. Brieﬂy,
DNA libraries were ampliﬁed from a single DNA fragment to millions of copies per
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bead using emulsion PCR Roche kits (GS Standard DNA Library Preparation kit;
GS FLX Standard emPCR kit (Shotgun); GS FLX PicoTiterPlate Kit (70 75); and
GS FLX Standard LR70 Sequencing Kit). Subsequent quality assessment and
quantitation were performed by 96-well plate ﬂuorometry using SpectroMax M5
(Molecular Devices) and analysed on a Bioanalyzer with Agilent RNA Pico 6000
LabChip Kit. Two 454-FLX Titanium sequencing runs (Roche) of 16 regions each
were carried out at the UCSD GeneChip Microarray Core facility. Subsequently,
Sanger sequencing was performed to achieve a better coverage of the 50 and 30 ends.
Splice isoform assembly and annotation. The 454 GS FLX sequencing data were
assembled and analysed to identify full-length alternatively spliced ORFs using the
in-house reference-based assembly pipeline (Supplementary Fig. 1, details in the
Supplementary Methods). In brief, raw 454 reads were processed and aligned to
human genome release hg19 using GMAP52. Each genomic position covered by
454 reads was annotated as either exonic or intronic based on quality scores.
Single-nucleotide polymorphisms and insertion/deletion (indel) variants were
called using SAMtools53. Additional Sanger sequencing was performed to improve
the assembly quality of the isoform terminal regions and was integrated using
Phred54 and CAP3 (ref. 55). To annotate splicing isoforms, all assembled contigs
were grouped into sets of unique isoforms deﬁned by the splicing patterns. To
assess isoform novelty, unique isoform sets were compared with ORF structures of
mRNAs from several major databases including CCDS, RefSeq, UCSC, Gencode
(Ensembl), MGC56 and human ORFeome57. Isoforms with exactly the same set of
splicing sites as annotated mRNAs were considered as known, whereas isoforms
with at least one novel splicing site were annotated as novel. The isoforms were
translated into protein sequences using the BioPython package. All isoforms that
produced short (o30 amino acid) proteins or had an out-of-frame indels within
the ﬁrst 20% of translated protein sequence were removed from subsequent
analysis to ensure high quality of annotation.
Experimental identiﬁcation of PPIs. The ASD422 ORFs were screened for PPIs
against the human ORFeome v5.1 (B15,000 ORFs) and against themselves using a
high-throughput Y2H system, retested and sequence validated (Supplementary
Fig. 2, details in the Supplementary Methods). First, ORFs of each isoform
(Iso-ORFs) were cherry-picked from Escherichia coli glycerol stocks, cultured and
cloned into pDEST-DB and pDEST-AD vectors using the Gateway recombination
LR reaction (Invitrogen). Iso-ORFs in the pDEST vectors were introduced into the
yeast strain Y8930 (MATa) to create the bait (DB-X) strains and into Y8800
(MATa) to create the prey (AD-Y) strains using lithium acetate transformation
method. DB-X strains that autoactivated transcription of the Gal1-HIS3 reporter
gene were detected and removed before the Y2H screens. The individual DB-X
strains (haploid Y8930 containing Iso-ORFs in the DB vector) were screened
against the pools of the AD-Y strains (haploid Y8800 containing human ORFeome
v5.1 prey in the AD vector) following standard Y2H protocols58. Positive colonies
were picked and used for making yeast lysates followed by yeast colony-PCR,
stitching PCR and 454 GS FLX sequencing59 to identify gene-level interaction pairs
(Supplementary Methods). Isoforms of the autism risk factors were also screened
against themselves (iso-ORF AD strains pooled). Four rounds of pair-wise Y2H
retests among isoforms of each gene as baits and a union of all interacting partners
from ORFeome 5.1/iso-ORF ADs for each gene as preys were performed in matrix
format. Only the interactions that scored positive at least three times in the retests
were retained. Sanger sequencing was performed to conﬁrm ORF-level interaction
pairs and to generate a high-conﬁdent isoform interactome network.
Validation of Y2H interactions by MAPPIT. To ensure that the interactions
detected by the Y2H are of a high quality, an orthogonal assay in mammalian cells,
MAPPIT28,60, was used to validate the interactions of 312 protein pairs. A random
set of ASIN interactions was selected following two steps. First, 400 gene-level
interacting protein pairs were randomly selected from the ASIN. Second, for those
pairs where more than one isoform was interacting with the same prey, only a
single isoform was randomly picked for the subsequent validation by MAPPIT. The
ﬁnal validation list, which consisted of 312 interaction pairs, was unique at the
gene-level and comparable to the reference sets. However, interactions from the
same gene were represented by different isoforms in some cases. The ASIN
validation rate was compared with the validation rate of the expanded PRS
consisting of B500 positive protein pairs and the expanded RRS consisting of
B700 random protein pairs29,60 using Mann–Whitney–Wilcoxon test.
ASIN quality assessment using functional annotations. We assessed functional
similarity of interacting protein pairs using four independent measures:
coexpression, coregulation, three branches of shared GO annotations and
co-occurrence of interacting proteins within the same protein complex with the
solved or homology-modelled protein structure. The frequencies of cofunctionally-
annotated protein pairs in ASIN were compared with those from the random
protein pairs set containing B1.2 million non-redundant protein pairs generated
by pairing each ASIN protein with each protein from the human ORFeome 5.1.
Relative Enrichment (RE) was calculated using the given threshold (PCC Z0.5, or
10th percentile for co-GO):
RE ¼
Cp
Np
Cr
Nr
ð1Þ
where Cp is the number of interacting gene pairs with coannotation above the
threshold; Np is the total number of PPI pairs in a network with functional data
available for both genes; Cr is the number of random gene pairs with coannotation
above the threshold; Nr is the total number of gene pairs with functional data
available for both genes. The statistical signiﬁcance of the enrichment was calcu-
lated using one-tailed Fisher’s exact test.
To identify coexpressed gene pairs, a publicly available human tissue expression
microarray dataset was obtained from NCBI Gene Omnibus (GEO accession
GSE7307) and pre-processed using robust multi-array method for background
correction. Only the expression proﬁles from 123 healthy tissues were included;
disease tissues and treated cell lines were not considered. Data ﬁltering process was
performed as follows: the probe sets with either 100% ‘absent’ calls across all
tissues, or expression values o20 in all samples, or an expression range o100
across all tissues were excluded from the analysis. The expression values from
replicated tissues were averaged into a single value. As a result, the expression
proﬁles for 14,958 human genes were obtained. Gene pairs with PCC40.5 were
considered to be coexpressed.
To identify coregulated gene pairs, the promoter region of each gene was
deﬁned as the region spanning 1000 base pairs upstream of the transcription start
site (TSS) and 500 base pairs downstream of the TSS. RefSeq mRNA annotations
were used to determine the TSS of each gene. The clustered transcriptional factor-
binding sites were downloaded from the ENCODE website (http://genome.ucs-
c.edu/ENCODE/) in BED format. Transcriptional factor-binding sites with BED
scores o800 were discarded as unreliable. The gene pairs with promoter regions
shared by at least one common transcription factor were considered to be
coregulated.
To identify co-GO-annotated gene pairs and to determine whether interacting
proteins share functional similarity, we analysed annotations extracted from the
GO database (http://www.geneontology.org/GO.downloads.database.shtml). GO
annotations inferred from Electronic Annotation were excluded from the analysis
as unreliable. Three GO branches (molecular function, cellular component and
biological process) were used for the analyses. GO annotations were ﬁrst ﬁltered
based on information content (IC). The IC of a GO term t is deﬁned as:
IC tð Þ ¼  ln½pðtÞ ð2Þ
where p(t) is the fraction of genes annotated with the term t or its descendants. GO
terms with ICo 0.95 (that is, those shared by more than 5% of all the annotated
genes in one GO branch) were discarded to avoid the ‘shallow annotation problem’.
After the ﬁltering, Gene Semantic Similarity Analysis and Measurement Tools
method61 was implemented to calculate the similarity score of gene pairs in each
GO branch.
To identify protein pairs with solved or modelled structures, for each protein
pair, the structural templates covering the interactions between domains of each
protein were derived using SUPERFAMILY, DOMMINO62 or PSI-BLAST. Once
the templates were obtained, the coverage of each template was further expanded
by using templates from the PDB (http://www.pdb.org/). A homology model of the
interaction was built using MODELLER63. All isoforms that participate in the
interactions covered by at least one template were analysed. The same pipeline was
used to assess the structural coverage of random background protein pairs.
ASIN analysis using CNV data. A list of 2,267 genes from the
de novo validated autism CNVs was assembled by literature curation of major de
novo CNV studies5–7,14,32, and a total of 69 genes from this list were successfully
mapped to the ASIN.
Since ASIN preys were identiﬁed using an unbiased screen against a library of
B15,000 ORFs, we used the comparable but much larger recently constructed HI-
II-11 (Supplementary Methods) for comparison with ASIN. Both, HI-II-11 and
ASIN, share the same prey search space (B15,000 ORFs), and they were both
generated in the same laboratory using similar experimental conditions.
Furthermore, these two networks have comparable proportions of the brain-
expressed preys (85% in ASIN versus 87% in HI-II-11, Supplementary Data 9),
making HI-II-11 the best currently available control PPI network for ASIN. The
interactions from the LCI dataset were used as an additional control
(Supplementary Methods).
To construct the CNV–prey network, all baits from the same CNVs were
merged into the CNV nodes. To perform statistical comparisons for Fig. 4b we
generated control CNV–prey networks containing the same number of CNVs as in
the ASIN CNV–prey network by randomly selecting genomic regions with the
same number of genes with interactions and the same number of interacting
partners as in ASIN. To ensure high quality of control networks, millions of them
were generated to randomly select the sets of 10,000 networks with exactly the
same parameters as ASIN CNV–preys network. Two sets of 10,000 networks each
were created: one using interactions from the HI-II-11 dataset, and the other using
LCI PPIs. These networks were used to estimate the statistical signiﬁcance of the
ASIN preys binding to multiple (Z2) unique CNVs in CNV–prey network
(Supplementary Table 2).
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The ASIN CNV–CNV network was constructed by merging both ASIN baits
and preys into the CNV nodes. To perform statistical comparisons for Figure 4c we
generated the sets of 10,000 control CNV–CNV networks containing the same
number of CNVs as in the ASIN CNV–CNV network by randomly selecting
genomic regions with the same number of genes with interactions as in ASIN. Two
sets of 10,000 networks each were created: one using interactions from the HI-II-11
dataset, and the other using LCI PPIs. These networks were used to estimate the
size of the largest connected component for comparison with ASIN
(Supplementary Table 2).
ASIN prey prioritization. To prioritize ASIN preys for Figure 5a, we ranked them
according to ten independent sources of evidence, ﬁve from our ASIN analyses and
ﬁve from the public domain. The ASIN-based sources of evidence included: (1)
preys binding to a signiﬁcantly greater than expected number of ASIN baits from
the de novo autism CNVs identiﬁed from the CNV–prey network (a total of 26);
(2) preys signiﬁcantly enriched in ‘SNARE/syntaxin binding’ and ‘transcription
factor binding’ from the gene coexpression and differential expression analysis (a
total of 29); (3) preys binding to a greater than expected number of ASIN baits (a
total of 14); (4) preys binding to two directly interacting ASIN baits and forming
network triplets (a total of 25); (5) preys with high network betweenness (a total of
22). The literature-derived sources of evidence included: (1) preys from the de novo
validated autism CNVs (a total of 45); (2) preys preferentially expressed in the
human brain (a total of 46); (3) preys present among post-synaptic density proteins
from the human neocortex (a total of 28); (4) preys annotated with psychiatric
phenotype in Online Mendelian Inheritance in Man (Supplementary Data 7) (a
total of 15); (5) preys representing fragile X mental retardation protein (FRMP)
binding targets (a total of 21).
To collect the sources of evidence we have performed additional ASIN analyses
as described below. To annotate preys for the Gene expression analysis in ASIN
category, the unsigned coexpression network for 205 ASIN genes with available
brain expression values12 was constructed by following the standard WGCNA
procedure64,65. The pair-wise correlation matrix was computed for each gene pair,
and an adjacency matrix was calculated by raising the correlation matrix to a power
of 10 using the scale-free topology criterion. Modules were deﬁned as branches of
the clustering tree and were characterized based on the expression of the module
eigengene (ME) or the ﬁrst principle component of the module. To obtain
moderately large and distinct modules, the minimum module size was set to ﬁve
genes and the minimum height for merging modules at 0.25. Genes were assigned
to a module if they had a high module membership (kME4 0.7). Five distinct
modules were detected in ASIN, and module 1 was signiﬁcantly enriched in genes
with ‘SNARE/syntaxin-binding’ and ‘transcription factor-binding’ functions.
To identify differentially-expressed genes that interact in ASIN, brain gene
expression data from autism patients and controls for 9552 genes was obtained12
and processed using the SAM package with the signiﬁcance threshold of false
discovery rate (FDR) o0.05 and fold changes 41.3. Two distinct modules of
interacting proteins, downregulated and upregulated in autism cases, were detected
in ASIN. Functional enrichment analyses were performed for each module from
WGCNA and differential expression analyses using DAVID, and statistical
signiﬁcance threshold was set at Po0.05 after Benjamini–Hochberg correction for
multiple comparisons.
To annotate preys for the Highly-connected ASIN prey category, we compared
the fraction of ASIN and HI-II-11 baits interacting with each ASIN prey that is
shared between ASIN and HI-II-11. We found that 14 ASIN preys interact with
greater than expected number of baits (one-tailed Fisher’s exact Po0.05 after false
discovery rate correction). The analysis was repeated by decreasing ASIN degree or
increasing HI-II-11 degree of each prey by a factor of one to ensure the robustness
of the results.
To annotate preys for the Binds two interacting ASIN baits category, the
clustering coefﬁcient Cx of each prey x was calculated as:
Cx ¼ 2pxNxðNx  1Þð Þ ð3Þ
where Nx is the number of bait neighbours of x and px is the number of the
connected pairs between all neighbours of x.
To annotate preys for the High betweenness category, a modiﬁed betweenness
was calculated by considering all shortest paths between ASIN baits. The
betweenness of a prey (vertex) v in ASIN network graph G¼ (V, E) was computed
as follows:
BðvÞ ¼
X
s 6¼ v 6¼ d2V
nsdðvÞ
nsd
ð4Þ
where nsd is total number of shortest paths from bait s to bait d, and nsd(v) is the
number of the paths that traverse prey v. The betweenness of a prey v was
calculated by summing B(v) overall pairs of vertices (s,d). High betweenness was
deﬁned as values in the top 25th percentile of the distribution (B(v)40.027).
To obtain sources of evidence from the literature, the expression proﬁles of
14,958 genes from 37 brain tissues and 86 other tissues (GSE7307 (ref. 66)) were
compared using a method developed by Raychaudhuri et al.67. A total of 2,577
genes were identiﬁed as Brain preferentially expressed with Po0.01 and 46 ASIN
preys overlapped with this list. Post-synaptic density genes from the human
neocortex (hPSD) (a total of 1459) were obtained from Baye´s et al.68 and 28 ASIN
preys overlapped with this list. To annotate ASIN preys as FRMP-binding target,
genes that are FMRP RNA targets in the mouse brain polyribosomes (a total of
839) were obtained from Darnell et al.69, and human orthologs of mouse genes
were mapped using Mammalian Orthology from the Mouse Genome Informatics.
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